# A Biomarker-Guided, Randomized, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With TRD

> **NCT05113771** · PHASE2 · COMPLETED · sponsor: **Denovo Biopharma LLC** · enrollment: 197 (actual)

## Conditions studied

- Treatment Resistant Depression

## Interventions

- **DRUG:** Liafensine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05113771
- **Lead sponsor:** Denovo Biopharma LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-29
- **Primary completion:** 2024-02-06
- **Final completion:** 2024-03-05
- **Target enrollment:** 197 (ACTUAL)
- **Last updated:** 2025-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05113771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05113771, "A Biomarker-Guided, Randomized, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With TRD". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05113771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*